PRESS RELEASE | Rubix LS is exploring Morocco
A team from Rubix LS will tag along with a delegate from the WHO to be dispatched to Western Africa for measuring health disparities and innovation within.
Lawrence, MA, January 24, 2018 - Rubix LS, an emerging Biotech advisory, consultancy and medical device firm, today announces that they will be working in tandem with the World Health Organization, to develop mechanisms that can transform some of the ecosystem's natural resources, within countries like Morocco, into disease treatment hubs.
"The team here at Rubix LS is obviously excited to be apart of program that really enforces the goodwill and innovation for good in places like Morocco" Said Reginald Swift, CEO of Rubix LS. "We're also emulating that innovation force within the city of Lawrence" Swift continued.
The company will be sending a team of 3 professionals ranging from engineers and scientist to conduct an exploratory evaluation of some of the health treatment disparities and illnesses that are usually found within the region. This will help bring to light some of the gaps of which multinational organizations can combine efforts to concentrate stemming diseases like Ebola, Zika, Black Plague and many other illnesses that are left untreated.
"We're hoping to illustrate a story to be told about focusing on developing innovative treatment options in under-represented nations, not just here but worldwide" Exclaimed Swift.
About Rubix LS:
Rubix LS., was founded in 2016 to merge advanced technologies in the life-science arena to advance the therapy options for patients who are suffering from rare and orphan cancers and diseases. Rubix LS is developing combination devices, varied within different disciplines, that utilizes regenerative matrices developed from their nanotechnology methodology to combat ailments in multiple manners. Rubix LS is leveraging the nano-matrices and innovatively merging them into implantable devices that can intelligently target, destroy and grow cells for patients to combat highly resistant cancers that otherwise are difficult to treat from radiation and chemotherapy.
Some statements in this press release are not historical facts and constitute "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of the company's management. Forward-looking statements are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. The reader is cautioned not to rely on these forward-looking statements. The company does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Media Contact Stacy Arrazcaeta firstname.lastname@example.org